Aphidicolin

Aphidicolin

SCHEMBL183956

C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@@]12CC[C@]3(O)CO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLA1 P09884 7/20 1.00
LMNA P02545 2/20 1.00
HTT P42858 1/20 1.00
RECQL P46063 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
HIF1A Q16665 1/20 1.00
CYP2C19 P33261 1/20 0.70
CYP3A4 P08684 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ALOX5 P09917 1/20 0.33
PTPN1 P18031 2/20 0.33
TOP2A P11388 1/20 0.33
HSD11B1 P28845 2/20 0.32
F3 P13726 3/20 0.31
CES2 O00748 1/20 0.31
CES1 P23141 1/20 0.31
USP2 O75604 1/20 0.31
USP7 Q93009 1/20 0.31
SLCO1B3 Q9NPD5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aphidicolin SCHEMBL14667945 1.00 POLA1 (1.00) POLA1LMNAHTTRECQLSMN1; SMN2
Aphidicolin SCHEMBL16610406 1.00 POLA1 (1.00) POLA1LMNAHTTRECQLSMN1; SMN2
Aphidicolin SCHEMBL8763668 1.00 POLA1 (1.00) POLA1LMNAHTTRECQLSMN1; SMN2
SCHEMBL14552897 0.84 LMNA (0.73) POLA1LMNAHTTRECQLSMN1; SMN2
Hydrochloric Acid SCHEMBL29351943 0.82 CYP2C19 (0.98) POLA1LMNAHTTRECQLSMN1; SMN2
Aphidicolin SCHEMBL2332951 0.77 POLA1 (0.59) POLA1LMNAHTTRECQLSMN1; SMN2
SCHEMBL15747 0.76 CYP2C19 (0.70) POLA1LMNAHTTRECQLSMN1; SMN2
Temoporfin SCHEMBL8660214 0.73 POLA1 (0.54) POLA1LMNAHTTRECQLSMN1; SMN2
SCHEMBL29483361 0.72 LMNA (0.56) POLA1LMNAHTTRECQLSMN1; SMN2
Stemodin SCHEMBL15978379 0.64 LMNA (0.47) POLA1LMNAHTTRECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 5380 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3841097-B1 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) 2026-05-20 EP claimed
US-12605407-B2 Methods to induce terminal differentiation in stem cells by interfering with DNA replication, methods of inducing pancreatic differentiation, and differentiated cells obtained thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2026-04-21 US claimed
EP-4346928-B1 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS US HEALTH (US) 2026-01-14 EP claimed
US-20250340836-A1 METHODS FOR PRODUCTION OF IPSCS NEW YORK STEM CELL FOUND INC (US) 2025-11-06 US claimed
US-20250325717-A1 ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-10-23 US claimed
US-20250320515-A1 GREENHOUSE-BASED PRODUCTION OF FUNGAL-DERIVED MEDICINAL COMPOUNDS UNIV NORTH TEXAS (US) 2025-10-16 US claimed
US-20250313647-A1 MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-10-09 US claimed
US-20250302977-A1 ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR ASSOCIATED PROTEIN (UPARAP) RIGSHOSPITALET (DK) 2025-10-02 US claimed
WO-2025202361-A1 ANTI-GPC1 ANTIBODIES AND USES THEREOF ADCENDO APS (DK) 2025-10-02 WO claimed
US-12428677-B2 Thermally responsive conjugates for DNA polymerase inhibition Tozaro Limited (GB) 2025-09-30 US claimed
WO-1996006863-A1 AGENTS FOR INDUCING APOPTOSIS AND APPLICATIONS OF SAID AGENTS IN THERAPY UNIVERSITY OF DUNDEE (GB) 1996-03-07 WO claimed
EP-0658117-A1 TREATMENT OF TUMORS WITH NEUROTROPHIC FACTORS AND CELL PROLIFERATION INHIBITORS THE WORCESTER FOUNDATION FOR BIOMEDICAL RESEARCH (US) 1995-06-21 EP claimed
US-5387520-A Contacting neuroblastoma cells with nerve growth factor and one of aphidicolin, hydroxyurea or thymidine for one to fifteen days WORCESTER FOUNDATION FOR EXPERIMENTAL BIOLOGY (US) 1995-02-07 US claimed
EP-0315782-B1 Method for the production of proteins THOMAE GMBH DR K (DE) 1994-09-28 EP claimed
WO-1994005315-A1 TREATMENT OF TUMORS WITH NEUROTROPHIC FACTORS AND CELL PROLIFERATION INHIBITORS WORCESTER FOUNDATION FOR EXPERIMENTAL BIOLOGY (US) 1994-03-17 WO claimed
US-5202244-A PROCESS FOR PRODUCING APHIDICOLIN USING THE MICRORGANISM VERTICILLIUM SP NIPPON MEKTRON LIMITED (JP) 1993-04-13 US claimed
US-5008252-A Using viricides 5'ethynyl-thymidine THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1991-04-16 US claimed
EP-0315782-A2 Method for the production of proteins Dr. Karl Thomae GmbH (DE) 1989-05-17 EP claimed
EP-0112603-B1 APHIDICOLANE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1987-03-04 EP claimed
EP-0112603-A1 Aphidicolane derivatives, their preparation and pharmaceutical compositions comprising them IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1984-07-04 EP claimed